Central Serous Chorioretinopathy Developed Following Covid-19 Vaccine
Retina-Vitreus
; 32(1):70-73, 2023.
Article
in English
| EMBASE | ID: covidwho-20234405
ABSTRACT
A 40-year-old male patient, an office worker, is a hospital staff. He applied with the complaint of sudden onset of blurred vision in the right eye. He stated that he had the first dose of inactivated covid vaccine (sinovac) 4 days ago in his story. In his examination, his vision was 0.5 in the right eye, 1.0 in the left eye, and his intraocular pressure was in both eyes. It was at the level of 15 mmHg. Biomicroscopically, the anterior segment looked natural. CSC was diagnosed in the FFA and OCT examinations.Treatment with oral acetazolamide (2x250 mg), topical nepafanac (4x1) was started. On the 13th day of the treatment, there was insufficient improvement in clinical findings, and oral acetazolamide was used. The dose was reduced (2x125 mg), oral epleronone (50 mg) was added. On the 70th day of the treatment, the vision in the right eye increased to full level in the control examination and it was observed that the retina returned to its normal appearance in the OCT examination.Copyright © 2023 Gazi Eye Foundation. All rights reserved.
corioretinopathy; covid; adult; article; case report; central serous retinopathy/di [Diagnosis]; central serous retinopathy/dt [Drug Therapy]; central serous retinopathy/si [Side Effect]; clinical article; coronavirus disease 2019/dt [Drug Therapy]; coronavirus disease 2019/pc [Prevention]; examination; eye; human; intraocular pressure; male; office worker; optical coherence tomography; pneumonia; slit lamp microscopy; visual acuity; acetazolamide/dt [Drug Therapy]; coronavac/ae [Adverse Drug Reaction]; coronavac/dt [Drug Therapy]
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Type of study:
Prognostic study
Topics:
Vaccines
Language:
English
Journal:
Retina-Vitreus
Year:
2023
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS